PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Rang in Aktien #1440
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktienkurs
$36.89
Marktkapitalisierung
$15.25B
Veränderung (1 Tag)
-1.28%
Veränderung (1 Jahr)
144.12%
Land
TW
Handel PharmaEssentia Corporation (6446)

Kategorie

Healthcare
Aktien-Split-Historie für PharmaEssentia Corporation (6446)
Die Aktie PharmaEssentia Corporation (Symbol: 6446) durchlief insgesamt 2 Aktiensplits.
Der letzte Aktiensplit fand am Jul 09, 2026 statt.
Eine 6446-Aktie, die vor dem Sep 11, 2025 gekauft wurde, entspricht heute 1.229881 6446-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
2026-07-09 1109:1000 x1.109 x1.229881
2025-09-11 1109:1000 x1.109 x1.109
Aktiensplits ähnlicher Unternehmen oder Wettbewerber